CO2023009063A2 - Constructos de expresión y usos de estos - Google Patents
Constructos de expresión y usos de estosInfo
- Publication number
- CO2023009063A2 CO2023009063A2 CONC2023/0009063A CO2023009063A CO2023009063A2 CO 2023009063 A2 CO2023009063 A2 CO 2023009063A2 CO 2023009063 A CO2023009063 A CO 2023009063A CO 2023009063 A2 CO2023009063 A2 CO 2023009063A2
- Authority
- CO
- Colombia
- Prior art keywords
- expression constructs
- polynucleotides
- methods
- disclosure
- interleukin
- Prior art date
Links
- 102000040430 polynucleotide Human genes 0.000 abstract 3
- 108091033319 polynucleotide Proteins 0.000 abstract 3
- 239000002157 polynucleotide Substances 0.000 abstract 3
- 102000015696 Interleukins Human genes 0.000 abstract 2
- 108010063738 Interleukins Proteins 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5434—IL-12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
- A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5123—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/50—Vector systems having a special element relevant for transcription regulating RNA stability, not being an intron, e.g. poly A signal
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Nanotechnology (AREA)
- Optics & Photonics (AREA)
- Dispersion Chemistry (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163135501P | 2021-01-08 | 2021-01-08 | |
| PCT/US2022/011841 WO2022150712A1 (en) | 2021-01-08 | 2022-01-10 | Expression constructs and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2023009063A2 true CO2023009063A2 (es) | 2023-07-21 |
Family
ID=80222240
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2023/0009063A CO2023009063A2 (es) | 2021-01-08 | 2023-07-06 | Constructos de expresión y usos de estos |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20240166707A1 (enExample) |
| EP (1) | EP4274846A1 (enExample) |
| JP (1) | JP2024503000A (enExample) |
| KR (1) | KR20230129479A (enExample) |
| CN (1) | CN116917309A (enExample) |
| AR (1) | AR124599A1 (enExample) |
| AU (1) | AU2022205679A1 (enExample) |
| CA (1) | CA3204373A1 (enExample) |
| CO (1) | CO2023009063A2 (enExample) |
| IL (1) | IL304118A (enExample) |
| MX (1) | MX2023008002A (enExample) |
| TW (1) | TW202241931A (enExample) |
| WO (1) | WO2022150712A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2023383367A1 (en) * | 2022-11-18 | 2025-05-29 | Trustees Of Boston University | Self-replicating rna and uses thereof |
| KR20260046366A (ko) | 2023-07-25 | 2026-04-07 | 스트랜드 세러퓨틱스 인코포레이티드 | 마이크로 rna 비표적화 센서를 포함하는 폴리뉴클레오타이드 및 이의 용도 |
| WO2025076415A1 (en) * | 2023-10-06 | 2025-04-10 | Seattle Children's Hospital D/B/A Seattle Children's Research Institute | Inducible transgenes encoding intracellular molecules for modulating immune cell function |
Family Cites Families (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
| US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
| CA1327358C (en) | 1987-11-17 | 1994-03-01 | Morio Fujiu | Fluoro cytidine derivatives |
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| AU744755B2 (en) | 1997-11-12 | 2002-03-07 | Brigham And Women's Hospital | The translation enhancer element of the human amyloid precursor protein gene |
| US7468275B2 (en) | 2000-01-28 | 2008-12-23 | The Scripps Research Institute | Synthetic internal ribosome entry sites and methods of identifying same |
| EP1259602A1 (en) | 2000-01-28 | 2002-11-27 | The Scripps Research Institute | Methods of identifying synthetic transcriptional and translational regulatory elements, and compositions relating to same |
| CA2462144C (en) | 2001-09-28 | 2016-09-20 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. | Micro-rna molecules |
| US7265096B2 (en) | 2002-11-04 | 2007-09-04 | Xenoport, Inc. | Gemcitabine prodrugs, pharmaceutical compositions and uses thereof |
| EP2530157B1 (en) | 2003-07-31 | 2016-09-28 | Regulus Therapeutics Inc. | Oligomeric compounds and compositions for use in modulation of miRNAs |
| ATE448312T1 (de) | 2003-09-26 | 2009-11-15 | Merck Serono Sa | Leitsequenzen zur verwendung bei der produktion von proteinen |
| CA2620420A1 (en) | 2005-08-24 | 2007-03-01 | The Scripps Research Institute | Translation enhancer-element dependent vector systems |
| CN101384273B (zh) | 2006-01-05 | 2013-07-10 | 俄亥俄州立大学研究基金会 | 胰腺内分泌和腺泡肿瘤中的微小rna表达异常 |
| EP2484782B1 (en) | 2006-01-05 | 2015-11-18 | The Ohio State University Research Foundation | MicroRNA-based methods and compositions for the diagnosis and treatment of solid cancers |
| ES2448491T3 (es) | 2006-03-02 | 2014-03-14 | The Ohio State University Research Foundation | Perfil de expresión de microARN asociado con cáncer de páncreas |
| WO2008036765A2 (en) | 2006-09-19 | 2008-03-27 | Asuragen, Inc. | Micrornas differentially expressed in pancreatic diseases and uses thereof |
| US8252538B2 (en) | 2006-11-01 | 2012-08-28 | The Ohio State University | MicroRNA expression signature for predicting survival and metastases in hepatocellular carcinoma |
| CN101622348A (zh) | 2006-12-08 | 2010-01-06 | 奥斯瑞根公司 | 作为治疗性干预靶标的miR-20调节的基因和途径 |
| US8415096B2 (en) | 2007-05-23 | 2013-04-09 | University Of South Florida | Micro-RNAs modulating immunity and inflammation |
| US20090099034A1 (en) | 2007-06-07 | 2009-04-16 | Wisconsin Alumni Research Foundation | Reagents and Methods for miRNA Expression Analysis and Identification of Cancer Biomarkers |
| CN101918594A (zh) | 2007-11-30 | 2010-12-15 | 俄亥俄州立大学研究基金会 | 肺癌中外周血中的微rna表达特征谱和靶向 |
| CN103911378A (zh) | 2007-12-11 | 2014-07-09 | 斯克利普斯研究所 | 涉及mRNA翻译增强因子的组合物和方法 |
| WO2009100430A2 (en) | 2008-02-08 | 2009-08-13 | Asuragen, Inc | miRNAs DIFFERENTIALLY EXPRESSED IN LYMPH NODES FROM CANCER PATIENTS |
| CA2717026A1 (en) | 2008-02-28 | 2009-09-03 | The Ohio State University Research Foundation | Microrna signatures associated with human chronic lymphocytic leukemia (ccl) and uses thereof |
| EP2112235A1 (en) | 2008-04-24 | 2009-10-28 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Compositions and methods for microRNA expression profiling of nasopharyngeal carcinoma |
| PL215513B1 (pl) | 2008-06-06 | 2013-12-31 | Univ Warszawski | Nowe boranofosforanowe analogi dinukleotydów, ich zastosowanie, czasteczka RNA, sposób otrzymywania RNA oraz sposób otrzymywania peptydów lub bialka |
| WO2010018563A2 (en) | 2008-08-12 | 2010-02-18 | Rosetta Genomics Ltd. | Compositions and methods for the prognosis of lymphoma |
| US9074206B2 (en) | 2008-11-13 | 2015-07-07 | Fudan University | Compositions and methods for micro-RNA expression profiling of colorectal cancer |
| EP2358902A1 (en) | 2008-12-10 | 2011-08-24 | Universität Regensburg | Compositions and methods for micro-rna expression profiling of cancer stem cells |
| WO2010129860A2 (en) | 2009-05-08 | 2010-11-11 | The Ohio State University Research Foundation | Microrna expression profiling and targeting in chronic obstructive pulmonary disease (copd) lung tissue and methods of use thereof |
| WO2011076142A1 (en) | 2009-12-24 | 2011-06-30 | Fudan University | Compositions and methods for microrna expession profiling in plasma of colorectal cancer |
| WO2011076143A1 (en) | 2009-12-24 | 2011-06-30 | Fudan University | Compositions and methods for microrna expression profiling of lung cancer |
| EP2341145A1 (en) | 2009-12-30 | 2011-07-06 | febit holding GmbH | miRNA fingerprint in the diagnosis of diseases |
| WO2011094683A2 (en) | 2010-01-29 | 2011-08-04 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Method of identifying myelodysplastic syndromes |
| EP2354246A1 (en) | 2010-02-05 | 2011-08-10 | febit holding GmbH | miRNA in the diagnosis of ovarian cancer |
| WO2011113030A2 (en) | 2010-03-11 | 2011-09-15 | H.Lee Moffitt Cancer Center & Research Institute | Human cancer micro-rna expression profiles predictive of chemo-response |
| WO2011157294A1 (en) | 2010-06-16 | 2011-12-22 | Universita' Degli Studi Di Padova | Compositions for use in treating or preventing cancer, breast cancer, lung cancer, ovarian cancer, metastasis, heart failure, cardiac remodelling, dilated cardiomyopathy, autoimmune diseases, or diseases or disorders related thereto |
| US20130230884A1 (en) | 2010-07-16 | 2013-09-05 | John Chaput | Methods to Identify Synthetic and Natural RNA Elements that Enhance Protein Translation |
| WO2012151212A1 (en) | 2011-05-01 | 2012-11-08 | University Of Rochester | Multifocal hepatocellular carcinoma microrna expression patterns and uses thereof |
| CA2835179A1 (en) | 2011-05-06 | 2012-11-15 | Xentech | Markers for cancer prognosis and therapy and methods of use |
| WO2013011378A1 (en) | 2011-07-15 | 2013-01-24 | Leo Pharma A/S | Diagnostic microrna profiling in cutaneous t-cell lymphoma (ctcl) |
| WO2013033640A1 (en) | 2011-09-01 | 2013-03-07 | Allegro Diagnostics Corp. | Methods and compositions for detecting cancer based on mirna expression profiles |
| JP2014529997A (ja) | 2011-09-23 | 2014-11-17 | ウニヴェルズィテート シュトゥットガルト | 免疫グロブリン結合ドメインを使った血清中半減期延長 |
| WO2013066678A1 (en) | 2011-10-26 | 2013-05-10 | Georgetown University | Microrna expression profiling of thyroid cancer |
| WO2013103659A1 (en) | 2012-01-04 | 2013-07-11 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Stabilizing rna by incorporating chain-terminating nucleosides at the 3'-terminus |
| ES2921623T3 (es) | 2012-11-26 | 2022-08-30 | Modernatx Inc | ARN modificado terminalmente |
| US20150167017A1 (en) | 2013-12-13 | 2015-06-18 | Moderna Therapeutics, Inc. | Alternative nucleic acid molecules and uses thereof |
| WO2015196118A1 (en) | 2014-06-19 | 2015-12-23 | Moderna Therapeutics, Inc. | Alternative nucleic acid molecules and uses thereof |
| EP3173092B1 (en) * | 2015-04-22 | 2019-06-26 | CureVac AG | Rna containing composition for treatment of tumor diseases |
| DK3458083T5 (da) * | 2016-05-18 | 2024-10-21 | Modernatx Inc | Polynukleotider, der koder for interleukin-12 (il12), og anvendelser heraf |
| CA3025812A1 (en) * | 2016-08-19 | 2018-02-22 | Curevac Ag | Rna for cancer therapy |
| TW202428301A (zh) | 2017-02-28 | 2024-07-16 | 法商賽諾菲公司 | 治療性rna |
| US11421011B2 (en) * | 2017-05-18 | 2022-08-23 | Modernatx, Inc. | Polynucleotides encoding tethered interleukin-12 (IL12) polypeptides and uses thereof |
| WO2020123716A1 (en) * | 2018-12-11 | 2020-06-18 | Obsidian Therapeutics, Inc. | Membrane bound il12 compositions and methods for tunable regulation |
-
2022
- 2022-01-10 AU AU2022205679A patent/AU2022205679A1/en active Pending
- 2022-01-10 CA CA3204373A patent/CA3204373A1/en active Pending
- 2022-01-10 MX MX2023008002A patent/MX2023008002A/es unknown
- 2022-01-10 US US18/260,831 patent/US20240166707A1/en active Pending
- 2022-01-10 TW TW111101009A patent/TW202241931A/zh unknown
- 2022-01-10 EP EP22703119.2A patent/EP4274846A1/en active Pending
- 2022-01-10 AR ARP220100043A patent/AR124599A1/es unknown
- 2022-01-10 WO PCT/US2022/011841 patent/WO2022150712A1/en not_active Ceased
- 2022-01-10 KR KR1020237026740A patent/KR20230129479A/ko active Pending
- 2022-01-10 JP JP2023541286A patent/JP2024503000A/ja active Pending
- 2022-01-10 CN CN202280018742.XA patent/CN116917309A/zh active Pending
-
2023
- 2023-06-28 IL IL304118A patent/IL304118A/en unknown
- 2023-07-06 CO CONC2023/0009063A patent/CO2023009063A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2022150712A1 (en) | 2022-07-14 |
| KR20230129479A (ko) | 2023-09-08 |
| TW202241931A (zh) | 2022-11-01 |
| CN116917309A (zh) | 2023-10-20 |
| CA3204373A1 (en) | 2022-07-14 |
| US20240166707A1 (en) | 2024-05-23 |
| JP2024503000A (ja) | 2024-01-24 |
| IL304118A (en) | 2023-09-01 |
| EP4274846A1 (en) | 2023-11-15 |
| MX2023008002A (es) | 2023-08-25 |
| AR124599A1 (es) | 2023-04-12 |
| AU2022205679A1 (en) | 2023-07-06 |
| AU2022205679A9 (en) | 2025-01-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2025002681A1 (es) | Anticuerpos anti-ceacam5 y sus conjugados y usos | |
| CO2022015650A2 (es) | Conjugados de anticuerpo-fármaco que comprenden agonistas de sting | |
| MX2016015952A (es) | Constructos de anticuerpo multiespecifico. | |
| CO2021007916A2 (es) | Ácido ribonucleico (arn) que codifica para una proteína | |
| CL2021001254A1 (es) | Vectores vegetales, composiciones y usos relacionados con los mismos | |
| PY2056649A (es) | Inmunocitoquina que comprende un complejo de proteína heterodimérico basado en il-15/il-15ra y su uso | |
| CO2022001977A2 (es) | Anticuerpos anti-cd96 y sus métodos de uso | |
| EP4223319A3 (en) | Method and molecules | |
| ECSP20020949A (es) | Conjugados de fármaco-anticuerpo (adc) anti-egfr y sus usos | |
| CO2023015212A2 (es) | Receptores quiméricos dirigidos a adgre2 y/o clec12a y usos de estos | |
| MX2023007228A (es) | Constructo de arn. | |
| CL2024003731A1 (es) | Compuestos tricíclicos de triazolo, inhibidores de dgk; uso para tratar cáncer. | |
| CL2024002358A1 (es) | Variante de fitasa; método de producción; composición; y su uso. | |
| MX2023008002A (es) | Constructos de expresion y usos de estos. | |
| MX2023007229A (es) | Constructo de arn. | |
| PE20241357A1 (es) | Anticuerpo biespecifico anti-cldn4/anti-cd137 | |
| UY40307A (es) | Macrociclos de indazol y su uso | |
| CO2020000231A2 (es) | Composiciones inmunogénicas que comprenden cea muc1 y tert | |
| CL2026000123A1 (es) | Constructo de vacuna y usos de este. | |
| CO2023016037A2 (es) | Anticuerpos anti-tigit, anticuerpos anti-cd96 y métodos de uso de estos | |
| CO2018007442A2 (es) | Vacunas contra el cáncer | |
| CL2020001494A1 (es) | Uso de una proteína no estructural de prv para proteger contra la inflamación del músculo esquelético y cardíaco. | |
| MX2024001328A (es) | Nuevas moleculas multiespecificas. | |
| PY2285025A (es) | Composiciones y métodos para la prevención y/o tratamiento de la covid-19 | |
| CL2020002308A1 (es) | Sistemas, aparatos, dispositivos y métodos para iniciar o detonar medios explosivos terciarios mediante energía fotónica |